TARS Stock Analysis: Buy, Sell, or Hold?
TARS - Tarsus Pharmaceuticals, Inc. Common Stock
$66.17
2.61 (4.11%)
▲
5d:
+6.98%
30d:
+4.24%
90d:
+3.18%
BUY
MODERATE Confidence
Analysis Updated: Jun 23, 2026 12:00 AM ET
Earnings: Aug 05, 2026
Get Alerted When TARS Hits Your Target Price
Join 10,000+ traders who never miss a move
You're in! Check your email to confirm and set your target price.
100% Free
No spam, ever
Unsubscribe anytime
Interactive Price Chart (1 Month)
Loading chart...
Loading historical data...
Bottom Line:
💡 BUY OPPORTUNITY: TARS shows positive signals but monitor for confirmation. Market pricing in 14.5% decline. Moderate conviction.
💡 BUY OPPORTUNITY: TARS shows positive signals but monitor for confirmation. Market pricing in 14.5% decline. Moderate conviction.
Long-Term Wealth Forecast (2031)
Based on Analyst Consensus Growth & Historical Valuation
0% (Stagnation)
50% (Hyper Growth)
EST. PRICE IN 2031
$100.42
Based on 7.0% avg growth
INTRINSIC VALUE TODAY
$62.35
Trading above historical range
How this is calculated: We use a Growth Decay Model: starting with analyst consensus growth (adjusted above) and gradually slowing it down to a long-term terminal rate (4%) by Year 5. This provides a more realistic valuation than assuming constant hyper-growth. We then apply a 25.0x Exit PE.
In-depth Analysis How we analyze
Valuation Analysis: TARS is currently trading at $66.17, which is considered extended relative to its 30-day fair value range of $59.50 to $63.28. From a valuation perspective, the stock is trading at a discount (Forward PE: 23.1) compared to its historical average (36.9). Remarkably, the market is currently pricing in an annual earnings decline of 14.5% over the next few years. This aligns with recent fundamental challenges.
Technical Outlook: Technically, TARS is in a downtrend. The price is approaching resistance at $66.48. A breakout above this level would be a bullish signal, while rejection here could lead to consolidation. The stock is showing strong short-term momentum, up 4.1% recently.
Market Sentiment: TARS has a strong technical setup (60/100), with favorable trendlines, momentum, and price action for short-term traders. Wall Street analysts see significant upside, with an average price target of $94.11 (+42.2%). Combining these factors, the current setup offers a favorable risk/reward ratio for buyers.
Technical Outlook: Technically, TARS is in a downtrend. The price is approaching resistance at $66.48. A breakout above this level would be a bullish signal, while rejection here could lead to consolidation. The stock is showing strong short-term momentum, up 4.1% recently.
Market Sentiment: TARS has a strong technical setup (60/100), with favorable trendlines, momentum, and price action for short-term traders. Wall Street analysts see significant upside, with an average price target of $94.11 (+42.2%). Combining these factors, the current setup offers a favorable risk/reward ratio for buyers.
Quick Decision Summary
Current Position
EXTENDED
Historical Trading Range
$59.50 -
$63.28
Company Quality Score
61/100
(BUY)
Volume Confirmation
HIGH
Confidence Score
66.7%
All Signals
- BEARISH: Price extended above range
- BULLISH: Strong technical setup (60/100)
- BULLISH: High volume confirmation
- BULLISH: Strong upward momentum (+4.1%)
- BULLISH: Trading 42.2% below Wall St target ($94.11)
Trading Range Analysis
30-Day Trading Range
$59.50 -
$63.28
Current vs Trading Range
EXTENDED
Support & Resistance Levels
Support Level
$60.08
Resistance Level
$66.48
Current Trend
Downtrend
Technical data as of
Jun 23, 2026
Fundamental Context
Forward P/E (Next Year Est.)
23.08
Wall Street Target
$94.11
(+42.2%)
Revenue Growth (YoY)
106.9%
Profit Margin
-9.0%
Valuation Discount vs History
-14.5% cheaper
PE vs Historical
23.1 vs 36.9
CHEAP
Market-Implied Price Targets
If current PE multiple persists
Implied Growth (YoY):
-14.5%
(market-implied from PE analysis)
1-Year Target
$59.55
(-10%)
2-Year Target
$53.60
(-19%)
3-Year Target
$48.24
(-27%)
3-Yr Target (if PE normalizes)
(PE: 23→37)
$77.11
(+17%)
💡
Upside Surprise Potential
If earnings stabilize (0% growth), PE could expand from 23.1 to 36.9
Stabilization Target:
$105.78
(+59.9%)
PE Expansion Potential:
+59.9%
Share & Embed Analysis
Last updated: June 24, 2026 8:07 AM ET
Data refreshes hourly during market hours. Next update: 9:07 AM
Data refreshes hourly during market hours. Next update: 9:07 AM
🔥 Top Stocks Breaking Out Now
| Ticker | Score | Recommendation | Change % |
|---|
Technical Signals Check
Is TARS showing a specific setup today?
Insider Activity (6 Months)
0
Buys
16
Sells
Net
INSIDERS SELLING
Recent Transactions
Bryan Wahl
SELL
4231 shares
2026-03-19
Dianne C Whitfield
SELL
4174 shares
2026-03-19
Elizabeth Yeu Lin
SELL
390 shares
2026-03-19
Top Rated Biotechnology Stocks
Top-rated stocks in Biotechnology by analyst ratings.
| Stock | Analyst Consensus | Analyst Target | Tradestie Score |
|---|---|---|---|
|
RARE
Ultragenyx |
STRONG BUY
20 analysts |
$52 | 64 BUY |
|
AXSM
Axsome Therapeutics Inc |
STRONG BUY
19 analysts |
$276 | 59 HOLD |
|
CYTK
Cytokinetics Inc |
STRONG BUY
21 analysts |
$105 | 62 BUY |
|
CRNX
Crinetics Pharmaceutical… |
STRONG BUY
17 analysts |
$83 | 61 BUY |
|
INCY
Incyte Corporation |
HOLD
27 analysts |
$109 | 60 BUY |
Advanced TARS Option Strategies
Professional options setups generated by AI based on today's TARS price and gamma walls.
